Emma Sangalang

574 total citations
10 papers, 254 citations indexed

About

Emma Sangalang is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Emma Sangalang has authored 10 papers receiving a total of 254 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Immunology, 3 papers in Oncology and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Emma Sangalang's work include Immunotherapy and Immune Responses (8 papers), Phagocytosis and Immune Regulation (5 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Emma Sangalang is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), Phagocytosis and Immune Regulation (5 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Emma Sangalang collaborates with scholars based in United States. Emma Sangalang's co-authors include Ons Harrabi, Tracy C. Kuo, Hong Wan, Laura V. Doyle, Jaume Pons, Amy Chen, Steven E. Kauder, Bora Han, Sangeetha Bollini and Jonathan T. Sockolosky and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Emma Sangalang

8 papers receiving 243 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emma Sangalang United States 6 211 76 51 42 28 10 254
Lucile Broyer Switzerland 6 141 0.7× 79 1.0× 30 0.6× 52 1.2× 60 2.1× 9 219
Jim Middelburg Netherlands 8 143 0.7× 179 2.4× 15 0.3× 70 1.7× 77 2.8× 13 308
Ludovica Arpinati Israel 9 184 0.9× 143 1.9× 32 0.6× 94 2.2× 10 0.4× 12 324
Haizeng Zhang China 4 131 0.6× 137 1.8× 21 0.4× 42 1.0× 7 0.3× 6 240
Martina Schuessler‐Lenz Germany 5 45 0.2× 89 1.2× 32 0.6× 104 2.5× 6 0.2× 8 197
Siham Farhane France 6 70 0.3× 105 1.4× 19 0.4× 25 0.6× 18 0.6× 7 162
Nela Klein-González Germany 7 243 1.2× 209 2.8× 8 0.2× 110 2.6× 15 0.5× 13 344
Kristi L. Manjarrez United States 7 182 0.9× 109 1.4× 12 0.2× 50 1.2× 14 0.5× 19 254
Galit Eisenberg Israel 12 193 0.9× 155 2.0× 11 0.2× 90 2.1× 11 0.4× 18 278
Frank Cichocki United States 7 271 1.3× 134 1.8× 9 0.2× 27 0.6× 7 0.3× 12 333

Countries citing papers authored by Emma Sangalang

Since Specialization
Citations

This map shows the geographic impact of Emma Sangalang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Sangalang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Sangalang more than expected).

Fields of papers citing papers by Emma Sangalang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emma Sangalang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Sangalang. The network helps show where Emma Sangalang may publish in the future.

Co-authorship network of co-authors of Emma Sangalang

This figure shows the co-authorship network connecting the top 25 collaborators of Emma Sangalang. A scholar is included among the top collaborators of Emma Sangalang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emma Sangalang. Emma Sangalang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Chen, Amy, Ons Harrabi, Min Li, et al.. (2024). Abstract 6746: A B-cell targeted TLR9 agonist antibody conjugate potentiates cancer vaccine efficacy and rejuvenates vaccine responses in the elderly. Cancer Research. 84(6_Supplement). 6746–6746. 1 indexed citations
2.
Chen, Amy, Min Li, Emma Sangalang, et al.. (2022). 1162 A nectin-4 targeted TLR9 agonist antibody conjugate induces robust immune cell activation and anti-tumor responses. Regular and Young Investigator Award Abstracts. A1205–A1205. 1 indexed citations
3.
Harrabi, Ons, Amy Chen, Emma Sangalang, et al.. (2021). 780 ALTA-002, a SIRPα-directed TLR9 agonist antibody conjugate activates myeloid cells and promotes anti-tumor immunity. SHILAP Revista de lepidopterología. A815–A815. 3 indexed citations
4.
5.
Kuo, Tracy C., Amy Chen, Ons Harrabi, et al.. (2020). Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity. Journal of Hematology & Oncology. 13(1). 160–160. 58 indexed citations
6.
Harrabi, Ons, Amy Chen, Emma Sangalang, et al.. (2020). 615 Targeted immune cell activation by systemic delivery of toll-like receptor 9 agonist antibody conjugates induce potent anti-tumor immunity. SHILAP Revista de lepidopterología. A369.2–A370.
7.
Sockolosky, Jonathan T., Emma Sangalang, Shelley Izquierdo, et al.. (2019). Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα. mAbs. 11(6). 1036–1052. 39 indexed citations
8.
Kauder, Steven E., Tracy C. Kuo, Ons Harrabi, et al.. (2018). ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLoS ONE. 13(8). e0201832–e0201832. 121 indexed citations
9.
10.
Caballero, Armando R., Davide Foletti, Aihua Tang, et al.. (2014). Effectiveness of Alpha-toxin Fab Monoclonal Antibody Therapy in Limiting the Pathology ofStaphylococcus aureusKeratitis. Ocular Immunology and Inflammation. 23(4). 297–303. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lucile Broyer Breakdown of academic impact, for papers by Jim Middelburg Breakdown of academic impact, for papers by Ludovica Arpinati Breakdown of academic impact, for papers by Haizeng Zhang Breakdown of academic impact, for papers by Martina Schuessler‐Lenz Breakdown of academic impact, for papers by Siham Farhane Breakdown of academic impact, for papers by Nela Klein-González Breakdown of academic impact, for papers by Kristi L. Manjarrez Breakdown of academic impact, for papers by Galit Eisenberg Breakdown of academic impact, for papers by Frank Cichocki
Rankless by CCL
2026